Triple Antiviral Therapy Promising for Mild-to-Moderate COVID-19
MONDAY, May 11, 2020 -- For patients with COVID-19, early triple antiviral therapy (lopinavir-ritonavir, ribavirin, and interferon beta-1b) is better than lopinavir-ritonavir for reducing the time to providing a nasopharyngeal swab negative for... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 11, 2020 Category: Pharmaceuticals Source Type: news
New triple antiviral drug combination shows early promise for treating COVID-19 in phase 2 randomized trial
A two-week course of antiviral therapy with interferon beta-1b plus lopinavir-ritonavir and ribavirin, started within 7 days of showing COVID-19 symptoms, is safe and more effective at reducing the duration of viral shedding than lopinavir-ritonavir alone in patients with mild to moderate illness, according to the first randomised trial of this triple combination therapy involving 127 adults (aged 18 and older) from six public hospitals in Hong Kong. (Source: World Pharma News)
Source: World Pharma News - May 11, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Combination of HIV, hepatitis C, MS drugs might resolve COVID-19 infection
Combination therapy with interferon beta-1b plus lopinavir-ritonavir and ribavirin appears to improve symptoms and shorten hospital stays for people with mild to moderate COVID-19. (Source: Health News - UPI.com)
Source: Health News - UPI.com - May 8, 2020 Category: Consumer Health News Source Type: news
Antiviral Trio Shows Mettle Against COVID-19
FRIDAY, May 8, 2020 -- A triple whammy of three antiviral drugs shows promise in fighting mild to moderate COVID-19, a new, small study suggests.
Two weeks of interferon beta-1b, lopinavir-ritonavir and ribavirin -- along with standard care -- was... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 8, 2020 Category: General Medicine Source Type: news
The Lancet: New triple antiviral drug combination shows early promise for treating COVID-19 in phase 2 randomized trial
(The Lancet) A two-week course of antiviral therapy with interferon beta-1b plus lopinavir-ritonavir and ribavirin, started within 7 days of showing COVID-19 symptoms, is safe and more effective at reducing the duration of viral shedding than lopinavir-ritonavir alone in patients with mild to moderate illness, according to the first randomized trial of this triple combination therapy involving 127 adults (aged 18 and older) from six public hospitals in Hong Kong. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - May 8, 2020 Category: Infectious Diseases Source Type: news
21.04.20: Bayer partners with Population Health Research Institute (PHRI) on global clinical research evaluating COVID-19 treatments
Bayer partners with Population Health Research Institute (PHRI) on global clinical research evaluating COVID-19 treatmentsInvestigation of combination therapies including Bayer's chloroquine and interferon beta-1b to foster much needed solutions for patients in fight against coronavirus pandemic / Bayer Canada to make CAD 1.5 million (approximately 1 million euros) financial commitment and to supply products in support of the research / Plans to include more than 60 contributing research locations involving 6.000 patientsmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - April 21, 2020 Category: Pharmaceuticals Source Type: news
Bayer partners with Population Health Research Institute (PHRI) on global clinical research evaluating COVID-19 treatments
Investigation of combination therapies including Bayer’s chloroquine and interferon beta-1b to foster much needed solutions for patients in fight against coronavirus pandemic / Bayer Canada to make CAD 1.5 million (approximately 1 million euros) financial commitment and to supply products in support of the research / Plans to include more than 60 contributing research locations involving 6.000 patients (Source: Bayer Company News)
Source: Bayer Company News - April 21, 2020 Category: Pharmaceuticals Source Type: news
Bayer partners with Population Health Research Institute (PHRI) on global clinical research evaluating COVID-19 treatments
Bayer announced today its Canadian organization Bayer Inc., Mississauga, Ontario, will partner with the Population Health Research Institute (PHRI) in launching a major clinical research program aimed at identifying potential treatments against COVID-19. The two studies will evaluate the safety and efficacy of different combination therapies including Bayer's chloroquine and interferon beta-1b. (Source: World Pharma News)
Source: World Pharma News - April 21, 2020 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news
Interferon Beta-1b (Betaseron, Extavia)
Title: Interferon Beta-1b (Betaseron, Extavia)Category: MedicationsCreated: 10/29/2018 12:00:00 AMLast Editorial Review: 10/29/2018 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - October 29, 2018 Category: Drugs & Pharmacology Source Type: news
Betaseron (Interferon beta-1b) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 2, 2018 Category: Drugs & Pharmacology Source Type: news
Bayer wins FDA nod for connected MS auto-injector
Bayer (ETR:BAYN) said yesterday that the FDA approved a supplemental biologics license application for the BetaConnect Navigator and myBetaApp – software for its electronic BetaConnect auto-injector.
The company’s BetaConnect auto-injector administers Betaseron for patients with relapsing-remitting multiple sclerosis. The newly-approved software allows patients to connect their device with the myBetaApp on their mobile device or computer and share data with their healthcare team.
Get the full story at our sister site, Drug Delivery Business News.
The post Bayer wins FDA nod for connected MS auto-injector appeared firs...
Source: Mass Device - May 31, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Neurological Pharmaceuticals Regulatory/Compliance Wall Street Beat Bayer AG Source Type: news
Medical News Today: MS: Treating earliest signs reduces risk of diagnosis, relapse
Researchers suggest treating the earliest signs of multiple sclerosis with interferon beta-1b could reduce the risk of diagnosis and reduce relapse rate. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 11, 2016 Category: Consumer Health News Tags: Multiple Sclerosis Source Type: news
Extavia (Interferon Beta-1b Kit) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 20, 2016 Category: Drugs & Pharmacology Source Type: news
interferon beta-1b (Betaseron, Extavia)
Title: interferon beta-1b (Betaseron, Extavia)Category: MedicationsCreated: 3/2/2005 12:00:00 AMLast Editorial Review: 6/15/2016 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - June 15, 2016 Category: Drugs & Pharmacology Source Type: news
BENEFIT 11: No new safety signals with interferon beta-1b
NEW ORLEANS – The long-term safety of interferon beta-1b for the treatment of multiple sclerosis is well established, and 11-year outcomes from the randomized, placebo-controlled BENEFIT trial... (Source: Family Practice News)
Source: Family Practice News - March 2, 2016 Category: Primary Care Source Type: news
